The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk.
Kindinger LM, Bennett PR, Lee YS, Marchesi JR, Smith A, Cacciatore S, Holmes E, Nicholson JK, Teoh TG, MacIntyre DA. · 2017
Read The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk. by Kindinger LM, Bennett PR, Lee YS, Marchesi JR, Smith A, Cacciatore S, Holmes E, Nicholson JK, Teoh TG, MacIntyre DA. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5244550.txt.
Introduction
Lindsay M. Kindinger and nine colleagues studied vaginal bacteria, cervical length, and progesterone treatment in women at risk of preterm birth, in Microbiome in 2017. Early birth is the leading cause of infant death worldwide. A short cervix in mid-pregnancy raises the risk, and vaginal progesterone lowers it for some women. The study followed 161 at-risk women with gene sequencing of vaginal samples.
At sixteen weeks, women whose vaginal community was dominated by the bacterium Lactobacillus iners were more likely to have a short cervix and to deliver before 34 weeks. Dominance by Lactobacillus crispatus pointed the other way, predicting full-term birth with high accuracy. A disordered vaginal mix by itself showed no such link. In women given progesterone, the treatment did not change the bacterial community or cancel the early-birth risk tied to L. iners, which also reassures patients using a vaginal pessary.
Catalog record
| CREATOR | Kindinger LM, Bennett PR, Lee YS, Marchesi JR, Smith A, Cacciatore S, Holmes E, Nicholson JK, Teoh TG, MacIntyre DA. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk By Lindsay M. Kindinger, Phillip R. Bennett, Yun S Lee, Julian R. Marchesi, Ann Smith, Stefano Cacciatore, Elaine Holmes, Jeremy K. Nicholson, T. G. Teoh, David A. MacIntyre Published in: Microbiome DOI: 10.1186/s40168-016-0223-9 ABSTRACT Background Preterm birth is the primary cause of infant death worldwide. A short cervix in the second trimester of pregnancy is a risk factor for preterm birth. In specific patient cohorts, vaginal progesterone reduces this risk. Using 16S rRNA gene sequencing, we undertook a prospective study in women at risk of preterm birth (n = 161) to assess (1) the relationship between vaginal microbiota and cervical length in the second trimester and preterm birth risk and (2) the impact of vaginal progesterone on vaginal bacterial communities in women with a short cervix. Results Lactobacillus iners dominance at 16 weeks of gestation was significantly associated with both a short cervix <25 mm (n = 15, P < 0.05) and preterm birth <34+0 weeks (n = 18; P < 0.01; 69% PPV). In contrast, Lactobacillus crispatus dominance was highly predictive of term birth (n = 127, 98% PPV). Cervical shortening and preterm birth were not associated with vaginal dysbiosis. A longitudinal characterization of vaginal microbiota (<18, 22, 28, and 34 weeks) was then undertaken in women receiving vaginal progesterone (400 mg/OD, n = 25) versus controls (n = 42). Progesterone did not alter vaginal bacterial community structure nor reduce L. iners-associated preterm birth (<34 weeks). Conclusions L. iners dominance of the vaginal microbiota at 16 weeks of gestation is a risk factor for preterm birth, whereas L. crispatus dominance is protective against preterm birth. Vaginal progesterone does not appear to impact the pregnancy vaginal microbiota. Patients and clinicians who may be concerned about “infection risk” associated with the use of a vaginal pessary during high-risk pregnancy can be reassured. Electronic supplementary material The online version of this article (doi:10.1186/s40168-016-0223-9) contains supplementary material, which is available to authorized users. BACKGROUND Preterm birth before 37 weeks of gestation is now the leading cause of death among children under the age of five [1]. An estimated 15 million babies are born preterm each year, and in the USA alone, the annual healthcare costs associated with those babies that survive is in excess of $25 billion [2]. Ascending bacterial infection from the vagina through the cervix into the uterine cavity is considered to be a major cause of spontaneous preterm birth [3–5]. Maternal host-vaginal microbial interactions throughout pregnancy are likely to play a fundamental role in reproductive health outcomes. Unlike other body sites where high bacterial diversity is considered beneficial to health [6, 7], a healthy vaginal community structure in pregnancy is dominated by only one, or a few, Lactobacillus species [8, 9]. These species provide protection against pathobiont colonization through excretion of lactic acid and production of antimicrobial compounds [10]. Assessment of vaginal microbial community structure can be performed using a variety of next generation sequencing and PCR-based platforms. The resulting data is typically analyzed using multivariate clustering approaches that permit comparison of individual taxa or community compositions [11–13]. A commonly used classification scheme involves hierarchical clustering analysis of 16S rRNA gene sequencing data into community state types (CSTs) as first described by Ravel and colleagues [13]. CSTs are typically dominated by one of four Lactobacillus species; Lactobacillus crispatus (CST I), Lactobacillus gasseri (CST II), Lactobacillus iners (CST III), and Lactobacillus jensenii (CST V). CST IV describes microbial communities largely devoid of Lactobacillus species and enriched mainly in anaerobic bacteria (CST IV). The composition of vaginal CSTs appears to be influenced by endogenous hormones, fluctuating with menses [14], the use of oral contraceptives [15] and onset of menopause [16], and estrogen supplementation in post-menopausal states [17]. In pregnancy, elevated concentrations of circulating estrogen drive glycogen accumulation in the vaginal epithelium, which is broken down by host α-amylase to complex sugar products such as maltotetraose, maltotriose, and maltose providing carbon sources preferentially utilized by Lactobacillus species [18]. This substrate availability leads to increased Lactobacillus species abundance and stability with advancing gestation and a decline in the number of women harboring microbial communities void of lactobacilli, with a dramatic change to reduced Lactobacillus dominance and increased diversity following estrogen withdrawal in the post-partum period [8, 19]. There is an association between Lactobacillus spp. depletion and vaginal dysbiosis and poor pregnancy outcomes including preterm birth [19] and late miscarriage [20], which appears to be patient cohort dependent [9]. Thus, the interplay between hormonal and metabolic signaling at the vaginal mucosa interface may act as a protective mechanism for the immuno-modulated pregnant mother, against exposure to pathogenic bacteria [21]. This may influence not only immediate pregnancy outcomes but also longer immunological health in the neonate such as allergy and asthma [22, 23]. This vaginal dysbiosis is present in between 2 and 27% of the population in pregnancy but does not always appear to be pathogenic [8, 24]. Recent evidence implicates L. iners dominance rather than dysbiosis for preterm birth risk in pregnancy [25]. L. iners is a vaginal commensal that has relatively recently been shown to be associated with dysbiosis [26, 27] and has been suggested as marker of microbial imbalance leading to BV [28]. The cervix serves as both a mechanical and chemical barrier to ascending bacteria [29]. Premature cervical ripening, a prerequisite for the expulsion of the fetus, may be triggered by exposure of the amniotic cavity to pathogenic bacteria ascending from the vagina [30], which drives a pro-inflammatory cytokine response, triggering prostaglandin release, and untimely cervical remodeling, softening, and dilation [31]. Premature cervical ripening is detectable by transvaginal ultrasound (TVS) several weeks prior to the onset of the clinical symptoms of preterm labor. Second trimester transvaginal cervical length measurements are considered a reliable and predictive tool for preterm birth and are frequently used for preterm birth surveillance [32]. Pregnant women with a short cervix, <25 mm before 24 weeks of gestation are considered at highest risk of preterm birth [33]. Early diagnosis of these pregnancies enables timely and targeted intervention by either cervical cerclage or vaginal progesterone therapy [34]. While both prevention strategies display comparable efficacy [35], progesterone supplementation is increasingly used as it negates the surgical risks associated with cerclage insertion such as maternal pyrexia, vaginal infection, bleeding, and subsequent requirement for cesarean section [36, 37] and has not been associated with any adverse neonatal effects [38, 39]. The mechanism of action of vaginal progesterone in the prevention of preterm birth involves its capacity to promote anti-inflammatory and pro-relaxant pathways in the uterus thereby reducing uterine contractility [40–43]. Endogenous progesterone is thought to largely exert anti-inflammatory downstream effects via progesterone receptor B-dominant signaling [43] to inhibit nitric oxide, prostaglandin, and cytokine production [41, 42]. This ultimately reduces myometrial contractility thereby inhibiting premature onset of labor [40]. Progesterone also exerts a quiescent effect on the cervix by limiting prostaglandin-induced collagenous remodeling of the cervical fibroblast [44–46]. Progesterone supplementation is therefore prescribed primarily for its systemic anti-inflammatory actions to maintain myometrial and cervical quiescence in high-risk pregnancies. In clinical studies, vaginal progesterone has been shown to attenuate the rate of cervical shortening [47, 48], but its efficacy in